TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17534686
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon alfa-2b (1 MU/m2 subcutaneously daily)
Study: 17534686
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with or without low-dose interferon alfa-2b
Study: 16701925
Drug: 3000 pfu
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 pfu Towne CMV vaccine with adjuvant recombinant interleukin-12 (rhIL-12)
Study: 16701925
Drug: 3000 pfu
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 pfu Towne CMV vaccine without adjuvant recombinant interleukin-12 (rhIL-12)
Study: 8795400
Drug: Pentosan polysulphate
Normalized name: Pentosan polysulphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentosan polysulphate sodium (PPS) 200 mg three times daily for 6 weeks
Study: 1825503
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg t.i.d. for 5-6 weeks)
Study: 31455871
Drug: scAT (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: scAT (subcutaneous abdominal adipose tissue)
Study: 31827657
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of preoperative and postoperative PVB (Group C)
Study: 23362336
Drug: No‐treatment control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No‐treatment control
Study: 17934830
Drug: rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 10 mg
Study: 24366288
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg (CYP2C19 PM phenotype)
Study: 24366288
Drug: rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 10 mg (CYP2C19 PM phenotype)
Study: 15206909
Drug: Apomorphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine 2 mg (titrated up to 3 mg if necessary)
Study: 15206909
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg (titrated up to 100 mg if necessary)
Study: 11452249
Drug: Ibutamoren mesylate
Normalized name: Ibutamoren Mesylate
DrugBank: Ibutamoren (DB18214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutamoren mesylate 0.8 mg/kg per day for 8 days (group III)
Study: 2839444
Drug: Post-operative thoracic
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative thoracic radiation without systemic chemotherapy
Study: 26353786
Drug: Collagen peptides
Normalized name: CASTOR OIL 100 g in 100 mL TOPICAL OIL [Anyi Beauty Biotin With Collagen Peptides Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen peptides (15 g/d)
Study: 19549022
Drug: Decision support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision support advising against nine potentially inappropriate medications
Study: 17634049
Drug: Xian-zhong injection
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xian-zhong injection
Study: 12583553
Drug: meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meropenem 500 mg i.v. t.i.d.
Study: 31888713
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray and loratadine tablets
Study: 21220074
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oral hydrocortisone
Study: 19371934
Drug: Amlodipine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine plus terazosin (5 mg Amlodipine + 2 mg terazosin)
Study: 19371934
Drug: Terazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (2 mg)
Study: 17376205
Drug: Local heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local heat therapy by radiofrequency (RF) at 50 degrees C for 30 s once weekly for 4 weeks
Study: 17376205
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of meglumine antimoniate once weekly for 4 weeks
Study: 15456084
Drug: Reverset (RVT)
Normalized name: edrophonium chloride Injectable Solution [Reversol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reverset (RVT) 10 mg
Study: 15456084
Drug: Reverset (RVT)
Normalized name: edrophonium chloride Injectable Solution [Reversol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reverset (RVT) 10-200 mg
Study: 10968096
Drug: Droperidol 0.625
Normalized name: droPERidol 0.625 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.625 mg and Metoclopramide 10 mg (Group II)
Study: 10968096
Drug: Droperidol 0.625
Normalized name: droPERidol 0.625 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.625 mg (Group I)
Study: 8440364
Drug: deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: deferred therapy where MP was started at the time of disease progression
Study: 3911367
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg at night
Study: 30244144
Drug: Subthreshold nanosecond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subthreshold nanosecond laser (SNL) treatment
Study: 31373520
Drug: Guided internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-delivered cognitive behavior therapy (ICBT) for panic disorder
Study: 25888515
Drug: Cont (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cont (no drugs)
Study: 11250999
Drug: High-dose alkylating
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alkylating agents (HDC) with autologous cellular support after doxorubicin-based therapy (AFM)
Study: 9385483
Drug: mibefradil 100
Normalized name: mibefradil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mibefradil 100 mg
Study: 9385483
Drug: diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diltiazem CD 360 mg
Study: 8487048
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (S) - six injections of triple intrathecal chemotherapy (TIC) consisting of methotrexate (MTX), hydrocortisone (HC), and cytarabine (ara‐C) during intensification and at every‐8‐week intervals for 17 additional doses.
Study: 2403586
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2 1-g capsules with each meal for 12 weeks)
Study: 1093506
Drug: Haloperidol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.25 mg/kg)
Study: 775883
Drug: Haloperidol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.05 mg/kg)
Study: 2649118
Drug: Haloperidol (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (high dose)
Study: 8329904
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg fentanyl added to 20 ml of 0.5% bupivacaine
Study: 8329904
Drug: 75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 μg fentanyl added to 20 ml of 0.5% bupivacaine
Study: 8329904
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg fentanyl added to 20 ml of 0.5% bupivacaine
Study: 26338457
Drug: GnRHAG +
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHAG + E2 (0.075 mg/d)
Study: 18429773
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil cream (70% lanolin, 30% olive oil)
Study: 18429773
Drug: Water-in-oil emollient
Normalized name: WATER IN OIL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-in-oil emollient cream (Bepanthen)
Study: 1591948
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific treatment mentioned)
Study: 10319057
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 2 mg daily
Study: 4028617
Drug: Bacampicillin 400
Normalized name: bacampicillin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 400 mg
Study: 4028617
Drug: Bacampicillin 800
Normalized name: bacampicillin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 800 mg
Study: 322607
Drug: Ampicillin 500
Normalized name: ampicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 500 mg
Study: 389824
Drug: Bacampicillin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin (all doses)
Study: 30012675
Drug: ATG (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (2.5 mg/kg) alone
Study: 25201708
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d carnosine for 14 days
Study: 9842837
Drug: Domperidone 20
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 20 mg
Study: 8846803
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg q.i.d.)
Study: 8846803
Drug: Diltiazem (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (mean 329 mg per day)
Study: 8846803
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg per day)
Study: 8846803
Drug: High-dose verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose verapamil
Study: 8846803
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (combined analysis)
Study: 25290743
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) with music during CWR exercise tests
Study: 24089511
Drug: GLP‐1 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1 (0.8 pmol/kg ⋅ min) continuous 24‐h infusion (prolonged)
Study: 24089511
Drug: GLP‐1 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1 (0.8 pmol/kg ⋅ min) two 4.5‐h infusions separated by 20 h (intermittent)
Study: 24089511
Drug: GLP‐1 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1 (0.8 pmol/kg ⋅ min) 4.5‐h infusion (acute)
Study: 21757667
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline (placebo)
Study: 9665112
Drug: Thrice-yearly deworming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-yearly deworming with 500 mg mebendazole
Study: 24464531
Drug: Alprazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.5 mg)
Study: 1927238
Drug: Lorazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2.5 mg) with warning signal
Study: 6749348
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg once daily
Study: 6749348
Drug: Chlorothiazide 500
Normalized name: chlorothiazide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide 500 mg twice daily
Study: 6749348
Drug: Chlorothiazide 500
Normalized name: chlorothiazide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide 500 mg once daily
Study: 6749348
Drug: Chlorothiazide 1000
Normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorothiazide 1000 mg once daily
Study: 25550296
Drug: Indirect moxibustion
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect moxibustion for 30 minutes daily, five sessions weekly for 4 weeks
Study: 10554529
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of sodium selenite
Study: 3515950
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 gm single dose)
Study: 26362564
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg dextromethorphan plus 100 mg sitagliptin
Study: 26362564
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sitagliptin alone
Study: 18922381
Drug: Waon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waon therapy
Study: 22677305
Drug: Diclofenac-K 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-K 12.5 mg liquid capsules
Study: 15956995
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving atypical antipsychotics
Study: 15956995
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving typical antipsychotics
Study: 7452872
Drug: No brain
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No brain treatment (control)
Study: 23408728
Drug: Naltrexone SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone SR (32 mg/day) plus bupropion SR (360 mg/day)
Study: 15102998
Drug: Standard-dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epinephrine (0.01 mg/kg)
Study: 16148823
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine (0.1 mg/kg)
Study: 15102998
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine (0.1 mg/kg) in asphyxia cases
Study: 15102998
Drug: Standard-dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epinephrine (0.01 mg/kg) in asphyxia cases
Study: 11452712
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg extended-release (ER) buspirone tablets
Study: 11452712
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg immediate-release (IR) buspirone tablets
Study: 3134359
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg three times daily for six weeks)
Study: 28219129
Drug: Propofol (3.5‐4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3.5‐4.0 μg/ml target controlled infusion)
Study: 14504152
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (applied 30 min before venepuncture)
Study: 7002524
Drug: Guanfacine (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (new antihypertensive drug)
Study: 26714385
Drug: Tolvaptan 15
Normalized name: tolvaptan 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 15 mg daily for 12 months
Study: 17628686
Drug: no immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: no immediate treatment
Study: 11500608
Drug: lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 60 mg once daily
Study: 1157027
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with VAC for patients with embryonal carcinoma of the ovary
Study: 1157027
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with VAC for advanced embryonal carcinoma of the ovary
Study: 1157027
Drug: Combined irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined irradiation and chemotherapy with vincristine and actinomycin-D
Study: 31331789
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg up to 150 mg every 2 weeks [COMBO I & II] or 150 mg every 2 weeks [LONG TERM])
Study: 23639822
Drug: Motion style
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motion style acupuncture treatment (MSAT)
Study: 22151475
Drug: Nonsteroidal anti‐inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti‐inflammatory drug (NSAID) injection (diclofenac)
Study: 17694218
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of 1% ropivacaine gel (ropivacaine‐20)
Study: 17694218
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of EMLA cream (EMLA‐60)
Study: 11799841
Drug: New bromazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: New bromazepam slow-release formulation
Study: 11799841
Drug: Conventional bromazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional bromazepam formulation
Study: 9516090
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa 2.5 mg daily for 2 weeks via Medic‐Aid Durable SideStream nebulizer (MMAD 2.1 microm)
Study: 9516090
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa 2.5 mg daily for 2 weeks via Hudson T Up‐draft nebulizer (MMAD 4.9 microm)
Study: 8194024
Drug: Etoposide 25
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 25 mg/m2/day
Study: 8194024
Drug: Etoposide 20
Normalized name: etoposide 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide 20 mg/m2/day
Study: 17883519
Drug: Zolmitriptan orally
Normalized name: Zolmitriptan Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan orally disintegrating tablets (ODT) 2.5 mg
Study: 12412823
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray 5 mg
Study: 17883519
Drug: Conventional zolmitriptan
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional zolmitriptan tablets 2.5 mg
Study: 23320402
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TDF)
Study: 16284584
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release morphine (SRM)
Study: 7716196
Drug: Tyrosine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine (100 mg/kg of body weight)
Study: 1097203
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline (5 mg)
Study: 25385408
Drug: Group fitness
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group fitness class for pregnant women, 60 min class with 40 min endurance training and 20 min strength training, performed at least twice per week for a minimum of 12 weeks
Study: 22136094
Drug: ER d‐MPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER d‐MPH (10, 20, 25‐30 mg)
Study: 14518664
Drug: Ticlopidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine plus aspirin (100 mg daily plus 81 mg daily)
Study: 14518664
Drug: Ticlopidine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine alone (200 mg daily)
Study: 1488568
Drug: Fenoterol/ipratropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol/ipratropium bromide combination (Berodual) by metered dose inhaler (MDI)
Study: 27183154
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.08 mg/kg)
Study: 30219062
Drug: High zinc
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High zinc biofortified wheat flour (HZn, 30 ppm zinc daily)
Study: 27454662
Drug: PLACEBO group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO group received placebo pills
Study: 1394916
Drug: oxantel pyrantel
Normalized name: oxantel
DrugBank: Oxantel (DB13670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxantel pyrantel pamoate composite (pyrantel pamoate 150 mg and oxantel pamoate 150 mg bid x 2d)
Study: 1394916
Drug: pyrantel pamoate
Normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrantel pamoate composite (base 10 mg/kg, single dose)
Study: 1394916
Drug: albendazole (400mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: albendazole (400mg, single dose)
Study: 3966851
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment groups with negative affective style (AS)
Study: 3966851
Drug: Home-based family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based family treatment groups with negative affective style (AS)
Study: 29039979
Drug: HLD200 (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLD200 (54 mg)
Study: 29453687
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg
Study: 9124670
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 ml (10 mg)
Study: 9124670
Drug: Intralipid 1
Normalized name: Intralipid 100 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 1 ml (control group)
Study: 30264073
Drug: Tea or
Normalized name: Acai, Chromium 100mcg, Ginseng, Green Tea Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea or cocoa flavanols (exact dosage and duration not specified)
Study: 26721220
Drug: Citron syrup
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citron syrup (15 ml, three times daily for 4 weeks)
Study: 26721220
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 mg tablet, three times daily for 4 weeks)
Study: 10333914
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin injected at -30 min before meal
Study: 10333914
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin injected at -15 min before meal
Study: 10333914
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin injected at 0 min (at meal)
Study: 7503007
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 to 100 mg/day, titrated to blood pressure and plasma potassium)
Study: 28857658
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg once daily, increased to 200 mg after 2 weeks)